GSK: treatment for ovarian cancer approved by EC
(CercleFinance.com) - GSK has said that the European Commission has approved Zejula (niraparib) as a first-line maintenance monotherapy treatment for advanced ovarian cancer.
GSK has also reported that the European Medicines Agency (EMA) has accepted regulatory submissions seeking approval for the use of the anti-IL5 biologic drug Nucala (mepolizumab).
Nucala is currently approved as an adjunctive treatment for patients with severe eosinophilic asthma in Europe. New submissions concern other pathologies, such as chronic rhinitis with nasal polyps and hypereosinophilic syndrome (HES) - if approved, Nucala would then become the only treatment indicated for use in four eosinophilic diseases in Europe.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
GSK has also reported that the European Medicines Agency (EMA) has accepted regulatory submissions seeking approval for the use of the anti-IL5 biologic drug Nucala (mepolizumab).
Nucala is currently approved as an adjunctive treatment for patients with severe eosinophilic asthma in Europe. New submissions concern other pathologies, such as chronic rhinitis with nasal polyps and hypereosinophilic syndrome (HES) - if approved, Nucala would then become the only treatment indicated for use in four eosinophilic diseases in Europe.
Copyright (c) 2020 CercleFinance.com. All rights reserved.